AI Article Synopsis

  • * The research utilized a large Spanish dataset that combined data from a population-based cohort and a biopsy-confirmed NASH cohort to estimate NASH fibrosis prevalence stages based on liver stiffness measurements (LSM).
  • * Findings indicated that approximately 3.21% of the adult population in Spain had elevated liver stiffness due to NAFLD, with the estimated prevalence of significant NASH fibrosis (F2-3) and cirrhosis being 1.33% and

Article Abstract

Background & Aims: Non-alcoholic fatty liver disease (NAFLD) has become a major public health problem, but the prevalence of fibrosis associated with non-alcoholic steatohepatitis (NASH) is largely unknown in the general population. This study aimed to provide an updated estimation of the prevalence of NASH fibrosis in Spain.

Methods: This was an observational, retrospective, cross-sectional, population-based study with merged data from two Spanish datasets: a large (N = 12 246) population-based cohort (ETHON), including transient elastography (TE) data, and a contemporary multi-centric biopsy-proven NASH cohort with paired TE data from tertiary centres (N = 501). Prevalence for each NASH fibrosis stage was estimated by crossing TE data from ETHON dataset with histology data from the biopsy-proven cohort.

Results: From the patients with valid TE in ETHON dataset (N = 11 440), 5.61% (95% confidence interval [95% CI]: 2.53-11.97) had a liver stiffness measurement (LSM) ≥ 8 kPa. The proportion attributable to NAFLD (using clinical variables and Controlled Attenuation Parameter) was 57.3% and thus, the estimated prevalence of population with LSM ≥ 8 kPa because of NAFLD was 3.21% (95% CI 1.13-8.75). In the biopsy-proven NASH cohort, 389 patients had LSM ≥ 8 kPa. Among these, 37% did not have significant fibrosis (F2-4). The estimated prevalence of NASH F2-3 and cirrhosis in Spain's adult population were 1.33% (95% CI 0.29-5.98) and 0.70% (95% CI 0.10-4.95) respectively.

Conclusions: These estimations provide an accurate picture of the current prevalence of NASH-related fibrosis in Spain and can serve as reference point for dimensioning the therapeutic efforts that will be required as NASH therapies become available.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541569PMC
http://dx.doi.org/10.1111/liv.15323DOI Listing

Publication Analysis

Top Keywords

prevalence nash
12
nash
8
transient elastography
8
nash fibrosis
8
biopsy-proven nash
8
nash cohort
8
ethon dataset
8
estimated prevalence
8
lsm ≥
8
≥ 8 kpa
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!